Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the first participant in Italy has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
Salem Media Group, Inc. (NASDAQ: SALM), announced today that it has acquired George Gilder's investment newsletters Gilder's Technology Report, Gilder's Technology Report PRO, Gilder's Moonshots, Gilder's Private Reserve and Gilder's Guideposts.